TABLE 2.
Overview of patient characteristics from data study
| Parameter | Patients without two neutrophil results | Patients with two neutrophil counts |
|---|---|---|
| Number of patients (N) | 3391 | 616 |
| Hospital | Hospital 1: 1690 (50%) | Hospital 1: 75 (12%) |
| Hospital 2: 1178 (34%) | Hospital 2: 107 (17%) | |
| Hospital 3: 523 (15%) | Hospital 3: 434 (70%) | |
| Age | Median 56 (18–90) | 56 (18–90) |
| Gender | Female: 2242 (66%) | 395 (64%) |
| Male: 1149 (34%) | 221 (36%) | |
| Tumour type | Breast: 1441 (42%) | Breast: 1618 (40%) |
| DLBCL: 363 (11%) | DLBCL: 572 (14%) | |
| Colorectal: 1587 (47%) | Colorectal: 1817 (45%) | |
| Regimen received | FEC: 713 (21%) | FEC: 130 (21%) |
| EC: 501 (15%) | EC: 17 (3%) | |
| T‐FEC: 230 (7%) | T‐FEC: 31 (5%) | |
| a RCHOP: 363 (11%) | a RCHOP: 207 (33%) | |
| FOLFOXIRI: 8 (0.2%) | FOLFOXIRI: 13 (2%) | |
| IRMDG: 576 (17%) | IRMDG: 631 (9%) | |
| a OXCAP: 324 (10%) | a OXCAP: 32 (5%) | |
| OXMDG: 679 (20%) | OXMDG: 809 (22%) | |
| Patients receiving cycle 1 treatment delay | 539 (20%) | |
| Baseline absolute neutrophil count | Median 4.62 range (0.4–72) | Median 4.63 range (0.5–51) |
| Performance status | 0–2: −3384 (99.8%) | 0–2: 611 (99%) |
| >2: 7 (0.2%) | >2: 5 (0.8%) | |
| Chemotherapy cycle length | ||
| 14 days | 1355 (40%) | 204 (33%) |
| 21 days | 2036 (60%) | 412 (67%) |
Abbreviations: DLBCL, diffuse large B cell lymphoma; FEC, fluorouracil, epirubicin and cyclophosphamide; T FEC, docetaxal, fluorouracil, epirubicin and cyclophosphamide; R‐CHOP, rituximab, cyclophosphamide, doxorubicin, vincristine and prednisolone; FOLFOXIRI, fluorouracil, oxaliplatin and irinotecan; IRMDG, irinotecan and fluorouracil; OXCAP, oxaliplatin and capecitabine; OXMDG, oxaliplatin and fluorouracil.
a
Combined for patients on 14 and 21 days schedule.